Maintenance Lurbinectedin in Combination With Serplulimab for Patients With ES-SCLC

Clinical trial NCT06497530 · RECRUITING

Trial details

NCT number: NCT06497530
Sponsor: Guangzhou Institute of Respiratory Disease
Status: RECRUITING
Phase: Phase 2
Study type: INTERVENTIONAL

Extensive-Stage Small Cell Lung Cancer

Start date: 2024-12-01
Primary completion: 2026-12-01
Enrollment: 30

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.